NBTX

NASDAQ Healthcare

Nanobiotix S.A. - ADSs

Biotechnology

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

🎯 投资策略评分

NBTX 在各投资策略中的评分。分数越高,越符合该策略目标。

高股息率 + 低波动性
高增长潜力(高贝塔 + 超卖)
逆向投资(超卖 + 低于移动均线)
超买股票(潜在做空标的)
大盘、机构级别股票
🔍 策略解读

最佳匹配: 🎈 Over-Hyped (55/100) — 此策略 超买股票(潜在做空标的).

评分最低的策略: 🔪 Falling Knife (21/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →

在文本中查找 NBTX in your text

粘贴任何文章、记录或帖子 — 工具将提取 NBTX 以及每一个其他隐藏的股票代码。

试试股票代码提取器 →

免责声明:本数据仅供教育和娱乐用途,不构成金融建议。市场数据可能存在延迟。在做出投资决策之前,请始终进行自己的研究。
数据最后更新: 2026-07-16.